LeonardJosephApplemanMD

Oncology • Pittsburgh, PA

Genitourinary Oncology

Associate Professor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Appleman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Appleman's full profile

Already have an account?

Office
5115 Centre Ave
Pittsburgh, PA 15232
Phone+1 412-692-4724

Fax+1 412-692-4905

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1995 - 1998
New York University School of MedicineClass of 1995

Certifications & Licensure

PA State Medical License 2006 - 2026
MA State Medical License 1998 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

A Study of Imatinib and Docetaxel in Prostate Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Study of Oxaliplatin and Taxotere in Prostate Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 1
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
COMPLETED
PHASE2
Study of GemOx and Vandetanib in Advanced Solid Malignancy Start of enrollment: 2009 Feb 01
Completed
Phase 1
Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma Start of enrollment: 2010 Oct 01
Terminated
Phase 1
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 1
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2012 Dec 06
Completed
Phase 1
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract Start of enrollment: 2004 Dec 17
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves
Clinical Cancer Research. 2024-12-16
1 citations
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Coh...
Evan Y Yu, Cristiano Ferrario, Mark D Linch, Michael Stoeckle, Brigitte Laguerre
European Urology Oncology. 2024-06-25
2 citations
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...
Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins
Journal of Clinical Oncology. 2024-06-10

Lectures

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metasta...
2019 ASCO Annual Meeting - 6/1/2019
Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual MeetingNovember 2nd, 2021
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCCJune 14th, 2019
No Benefit from Pazopanib in Advanced Kidney Cancer After Surgery to Remove MetastasesJune 3rd, 2019
Join now to see all